Phenobarbitone in essential tremor.
We conducted a double-blind, placebo-controlled trial of phenobarbitone on a fixed-dose regimen in 12 patients with essential tremor. The drug was better than placebo on accelerometric measurement and clinical assessment, but not according to patient self-assessment or measures of manual performance. Phenobarbitone may be an alternative to beta-adrenoreceptor antagonists in treating essential tremor.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010634:Phenobarbital / Q000627:therapeutic use*; D010919:Placebos; D014202:Tremor / Q000188:drug therapy*
D010919:Placebos; D010634:Phenobarbital